Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573161 | 0.88 | SLC40A1 (0.40) | SLC40A1KCNH2SLC2A1PARP1DRD2 | |
| SCHEMBL14573148 | 0.86 | KCNH2 (0.47) | SLC40A1KCNH2SLC2A1 | |
| SCHEMBL5766014 | 0.81 | CHRM3 (0.41) | SLC40A1KCNH2 | |
| SCHEMBL5765657 | 0.79 | KCNH2 (0.47) | SLC40A1KCNH2SLC2A1 | |
| SCHEMBL5774180 | 0.75 | KCNH2 (0.42) | SLC40A1KCNH2SLC2A1 | |
| SCHEMBL6661601 | 0.72 | KCNH2 (0.45) | SLC40A1KCNH2SLC2A1 | |
| SCHEMBL5634581 | 0.71 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL5657093 | 0.68 | CHRNA7 (0.47) | SLC40A1PARP1DRD2 | |
| SCHEMBL5656451 | 0.67 | KDM4E (0.53) | SLC40A1 | |
| SCHEMBL6214270 | 0.66 | KCNH2 (0.51) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | disclosed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | SLC40A1 1242/4885KCNH2 3267/4885SLC2A1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.